View Our Clinical Trials

office@woendo.com

(407) 480-4830

1510 Citrus Medical Ct
Ocoee, FL 34761

Clinical Trials

What Are Clinical Trials?

Participating in a clinical trial is more than contributing to research — it’s a proactive choice for your health. Clinical trials give you access to advanced medical care, often including more frequent monitoring, additional diagnostic testing, and expert oversight from highly trained healthcare teams.

Participants may also receive investigational treatments that are not yet available to the public but have already shown promising results. These therapies often represent the latest medical breakthroughs, offering hope and potential benefits beyond today’s standard care.

Beyond personal health benefits, participants are often compensated for their time and travel, making involvement even more accessible and attractive. Most importantly, by joining a clinical trial, you’re directly shaping the future of medicine — helping to bring better treatments to yourself and others.

Why Consider Participating in a Clinical Trial?

✔ Care at No Cost
Qualifying participants receive high-quality medical care completely free of charge — including health checkups, specialized testing, and ongoing monitoring that might otherwise be expensive or hard to access.

✔ Access to Cutting-Edge Treatments
Be among the first to access innovative therapies and medications that are not yet widely available. These investigational treatments are provided at no cost to eligible participants.

✔ Compensation and Support
Most studies provide compensation for time, travel, and participation, in addition to covering all study-related expenses.

✔ Make a Meaningful Impact
By joining, you’re not only exploring a new care option for yourself — you’re also helping advance medical research and shape tomorrow’s treatments.

✔ Gain Insight and Empowerment
Through regular health monitoring, you gain a deeper understanding of your condition and develop more confidence in managing your health.

✔ Work with Leading Specialists
Our trials are conducted by experienced physicians and research teams dedicated to your care and the advancement of medicine.

Current Areas of Research

  • Type 1 Diabetes

  • Type 2 Diabetes & Obesity

  • Obesity

  • Chronic Kidney Disease

  • Hypothyroidism

Don’t Wait — Call Us Today

Spaces in clinical trials are limited, and enrollment is happening now. If you’ve been considering participation, this is the time to take action.

Call us today to learn more about our active trials, discuss eligibility, and find out if a clinical trial could

 be the right option for you. Your call could be the first step toward accessing tomorrow’s medicine — today.

Active – Recruiting:

Onward 11 / NN1436-8181

  • Condition:  Type 1 Diabetes 
  • Status: Active – Recruiting
  • Sponsor: NovoNordisk
  • Type of Study:  Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
  • Study Length: 26 Weeks
  • Target Age/Sex: ≥18
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria, please visit: https://www.clinicaltrials.gov/study/NCT07076199
  • To fill out a pre-screening survey, please visit: Pre-Screening Form

Zupreme 2 / ZP8396-24115

  • Condition: Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
  • Status: Active – Recruiting
  • Sponsor: Zealand Pharma
  • Type of Study: Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
  • Study Length: 28 Weeks
  • Target Age/Sex: ≥18
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria, please visit: Zupreme 2
  • To fill out a pre-screening survey, please visit: Pre-Screening Form

GZPO

  • Condition: Obesity or Overweight and Type 2 Diabetes (GZPO)
  • Status: Active – Recruiting
  • Sponsor: Eli Lilly
  • Type of Study: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes (GZPO)
  • Study Length: 78 Weeks
  • Target Age/Sex: ≥18
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria, please visit: https://clinicaltrials.gov/study/NCT06972472https://classic.clinicaltrials.gov/ct2/show/NCT04419779 
  • To fill out a pre-screening survey, please visit: Pre-Screening Form

ReCET / 898

  • Condition: Type II Diabetes
  • Status: Active – Recruiting
  • Sponsor: Endogenex
  • Type of Study: A Multicenter, Randomized, Double-blind, Sham-controlled study for Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals with Type II Diabetes.
  • Study Length: 52 Weeks
  • Target Age/Sex: 18 Years to 70 Years   (Adult, Older Adult)
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • Check Procedure Video: https://www.endogenex.com/recet/
  • To check eligibility criteria, please visit: https://clinicaltrials.gov/study/NCT06267391
  • To fill out a pre-screening survey, please visit: Pre-Screening Form

BaxDuo Pacific / D6972C00002

  • Condition: Chronic Kidney Disease with Proteinuria
  • Status: Active – Recruiting
  • Sponsor: AstraZeneca
  • Type of Study: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin in Participants with Chronic Kidney Disease and High Blood Pressure – BaxDuo-Pacific
  • Study Length: 24 months
  • Target Age/Sex:18 Years to 130 Years (Adult, Older Adult)
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria, please visit: https://classic.clinicaltrials.gov/ct2/show/NCT04419779 
  • To fill out a pre-screening survey, please visit: Pre-Screening Form

BaxDuo Artic / D6972C00003

  • Condition: Chronic Kidney Disease with Proteinuria
  • Status: Active – Recruiting
  • Sponsor: AstraZeneca
  • Type of Study: A Phase III, Randomised, Double-Blind, Active-controlled Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants With CKD and High Blood Pressure
  • Study Length: 24 months
  • Target Age/Sex:18 Years to 130 Years (Adult, Older Adult)
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria, please visit: https://classic.clinicaltrials.gov/ct2/show/NCT04419779 
  • To fill out a pre-screening survey, please visit: Pre-Screening Form

Solstice / D761C00001

  • Condition: Type II Diabetes
  • Status: Active – Recruiting
  • Sponsor: AstraZeneca
  • Type of Study: Efficacy, Safety, and Tolerability of Once-Daily Oral Administration of AZD5004 versus Placebo for 26 Weeks in Adults with Type 2 Diabetes Mellitus.
  • Study Length: 26 Weeks
  • Target Age/Sex: ≥18
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria, please visit: https://clinicaltrials.gov/study/NCT06267391
  • To fill out a pre-screening survey, please visit: Pre-Screening Form

Avanti / M21-341

    • Condition: Hypothyroidism
    • Status: Active – Recruiting
    • Sponsor: AbbVie
    • Type of Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypo
      thyroidism
    • Study Length: 81 Weeks
    • Target Age/Sex: 18 Years to 75 Years   (Adult, Older Adult)
    • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
    • To check eligibility criteria, please visit: https://classic.clinicaltrials.gov/ct2/show/NCT06345339
    • To fill out a pre-screening survey, please visit: Pre-Screening Form